Glucotrack, Inc.

Snapshot

GlucoTrack has no revenue and lost $19.4M in FY 2025, with operating cash burn of $15.2M against just $1.1M of cash. Signal8 models roughly 8.2 months of runway.

What's Happening Right Now

• Thu 22nd Oct '26 · Reverse split: Glucotrack effected a second reverse split in two months (1-for-2 on Oct 26, 2026, after a 1-for-15 split on Aug 28, 2026) to try to hold Nasdaq's $1.00 minimum bid price through Nov 9, 2026.
• Thu 22nd Oct '26 · Offering: Raised $2.00M in gross proceeds through a private placement (PIPE), with warrants over 4.09M shares and a $2.56M convertible note.
• Mon 19th Oct '26 · Warrant waiver: On Oct 13, 2026, Glucotrack signed a Waiver Agreement with warrant holders, issuing 406,198 new warrants at a $7.50 strike in exchange for removing a restriction on issuing new equity and eliminating a price-reset ratchet.
• Wed 14th Oct '26 · Dilution vote: A preliminary proxy filed Oct 14, 2026 asks shareholders to clear Nasdaq rules for shares tied to an $11.6M convertible note deal and a PIPE warrant, which together could exceed 20% of shares outstanding, plus another reverse-split authorization.
• Wed 14th Oct '26 · Resale registration: An Oct 14, 2026 S-1/A registers resale of up to 43.2 million shares (about 1,825% of shares outstanding) tied to bridge notes, an ELOC, and PIPE financings, alongside a disclosed $156.2M accumulated deficit and auditor going-concern doubt.
• Tue 13th Oct '26 · Warrants: Issued warrants over 203K shares.
• Fri 25th Sep '26 · Offering: Raised $3.10M in gross proceeds through a registered direct offering, with warrants over 675K shares.
• Fri 14th Aug '26 · Going concern: The 10-Q for the quarter ended June 30, 2026 disclosed substantial doubt about the company's ability to continue as a going concern, with $1.1M cash and a $1.7M stockholders' deficit.